CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
Sheng-Mou Hsiao, Chun-Hou Liao, Ho-Hsiung Lin, Hann-Chorng Kuo
Int Neurourol J. 2015;19(3):171-177.   Published online 2015 September 22
DOI: https://doi.org/10.5213/inj.2015.19.3.171

Excel Download

Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
International Neurourology Journal. 2015;19(3):171-177   Crossref logo
Link1 Link2

Factors involved in the success of antimuscarinic treatment
BJU International. 2002;83(S2):42-47   Crossref logo
Link1

Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
International Journal of Clinical Practice. 2010;64(9):1287-1293   Crossref logo
Link1

Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year
LUTS: Lower Urinary Tract Symptoms. 2016;   Crossref logo
Link1

Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response
BJU International. 2003;92(4):415-417   Crossref logo
Link1

Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
LUTS: Lower Urinary Tract Symptoms. 2016;   Crossref logo
Link1 Link2 Link3

690 Can baseline characteristics of subjects with overactive bladder predict responsiveness to antimuscarinic treatment
European Urology Supplements. 2012;11(1):e690-e690a   Crossref logo
Link1 Link2

Re: Risk Factors for the Failure of Antimuscarinic Treatment with Solifenacin in Women with Overactive Bladder
The Journal of Urology. 2014;191(6):1822-1825   Crossref logo
Link1 Link2

MP09-13 CLINICAL EFFICACY AND SAFETY OF FULL DOSE ANTIMUSCARINIC AGENT TREATMENT ON UNSATISFACTORY IMPROVEMENT OF SYMPTOMS AFTER LOW DOSE ANTIMUSCARINIC TREATMENT IN MALE PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE MULTICENTER STUDY
The Journal of Urology. 2017;197(4):e104-e105   Crossref logo
Link1 Link2

Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy
PLoS ONE. 2013;8(10):e76706   Crossref logo
Link1